Official websites use .gov
Secure .gov websites use HTTPS
Aducanumab for Alzheimer’s disease: effectiveness and value : final evidence report and meeting summary
Aducanumab for Alzheimer’s disease: effectiveness and value : final evidence report and meeting summary
- Collection:
- Health Policy and Services Research
- Author(s):
- Lin, Grace A., author
Whittington, Melanie D., author
Synnott, Patricia G., author
McKenna, Avery, author
Campbell, Jon, author
Pearson, Steven D., author
Rind, David M., author - Contributor(s):
- California Technology Assessment Forum, issuing body.
Institute for Clinical and Economic Review, issuing body. - Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 5, 2021
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Alzheimer Disease -- drug therapy
Antibodies, Monoclonal
United States - Genre(s):
- Technical Report
- Abstract:
- Alzheimer’s disease (AD) is a fatal neurodegenerative brain disease characterized by the progressive accumulation of beta-amyloid protein plaques and neurofibrillary tangles; these are hypothesized to damage neurons and lead to the loss of cognition and physical functioning. AD affects almost six million people in the United States (US), with more women than men affected and Black Americans at a higher risk of developing the disease. Symptoms of AD include impairment of memory, language, executive function, and visuospatial function that affects one’s ability to function. Other symptoms include changes in mood or personality and sleep disturbances. Eventually, patients may require around-the-clock in-home or institutional care. The average life expectancy of patients with AD is four to eight years. As the disease progresses, caregiver impact—most often done by unpaid family members and friends—increases significantly. Caregivers can suffer significant negative physical, financial, and emotional outcomes from the strain of caregiving. Current treatment of AD is focused on supportive care, which may include treatment of dementia symptoms with medications that do not alter the course of the disease. Because of the devastating burden of AD, there is a great need for disease-modifying treatments that slow or stop progression of the disease. Aducanumab (“aducanumab-avwa”; Aduhelm™, Biogen), a human monoclonal antibody that promotes clearance of beta-amyloid plaques from the brain, is a potentially disease-modifying treatment that was granted accelerated approval by the US Food and Drug Administration (FDA) on June 7, 2021 for patients with AD. It is given as an intravenous (IV) infusion every four weeks.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918401087306676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918401087306676